[go: up one dir, main page]

WO2007059905A3 - Thienopyrimidines treating inflammatory diseases - Google Patents

Thienopyrimidines treating inflammatory diseases Download PDF

Info

Publication number
WO2007059905A3
WO2007059905A3 PCT/EP2006/011081 EP2006011081W WO2007059905A3 WO 2007059905 A3 WO2007059905 A3 WO 2007059905A3 EP 2006011081 W EP2006011081 W EP 2006011081W WO 2007059905 A3 WO2007059905 A3 WO 2007059905A3
Authority
WO
WIPO (PCT)
Prior art keywords
inflammatory diseases
thienopyrimidines
treating inflammatory
treating
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2006/011081
Other languages
French (fr)
Other versions
WO2007059905A9 (en
WO2007059905A2 (en
Inventor
Steven Taylor
Steven Murfin
Thomas Stephen Coulter
Stefan Jaekel
Babette Aicher
Arndt-Rene Kelter
Joachim Kraemer
Christian Kirchhoff
Andreas Scheel
Julian Woelke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Develogen AG
Original Assignee
Develogen AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Develogen AG filed Critical Develogen AG
Publication of WO2007059905A2 publication Critical patent/WO2007059905A2/en
Publication of WO2007059905A3 publication Critical patent/WO2007059905A3/en
Publication of WO2007059905A9 publication Critical patent/WO2007059905A9/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to the use of thienopyrimidine compounds for the production of pharmaceutical compositions for the treatment of inflammatory diseases.
PCT/EP2006/011081 2005-11-25 2006-11-17 Thienopyrimidines treating inflammatory diseases Ceased WO2007059905A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05025772.4 2005-11-25
EP05025772 2005-11-25

Publications (3)

Publication Number Publication Date
WO2007059905A2 WO2007059905A2 (en) 2007-05-31
WO2007059905A3 true WO2007059905A3 (en) 2007-08-02
WO2007059905A9 WO2007059905A9 (en) 2007-11-01

Family

ID=37682624

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/011081 Ceased WO2007059905A2 (en) 2005-11-25 2006-11-17 Thienopyrimidines treating inflammatory diseases

Country Status (1)

Country Link
WO (1) WO2007059905A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200802118A1 (en) 2006-04-07 2009-04-28 Девелоджен Ациенгезельшафт HAVING INHIBITING ACTIVITY WITH RESPECT TO MNK1 / MNK2 THYENOPYRIMIDINES INTENDED FOR USE IN PHARMACEUTICAL COMPOSITIONS
EP1889847A1 (en) 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidines for pharmaceutical compositions
WO2009065596A2 (en) * 2007-11-22 2009-05-28 Develogen Aktiengesellschaft Use of mnk inhibitors for the treatment of alzheimer's disease
US8802849B2 (en) 2008-02-19 2014-08-12 Vichem Chemie Kutató Kft. Tricyclic benzo[4,5]thieno-[2,3-d]pyrimidine-4-yl-amin derivatives, their salts, process for producing the compounds and their pharmaceutical use
NZ591113A (en) 2008-08-26 2012-07-27 Boehringer Ingelheim Int Thienopyrimidine linked to phenyl or pyridine via an nh amine for pharmaceutical compositions
US20120122889A1 (en) 2008-12-23 2012-05-17 President And Fellows Of Harvard College Small molecule inhibitors of necroptosis
AR080328A1 (en) * 2010-02-26 2012-03-28 Boehringer Ingelheim Int TIENOPIRIMIDINES CONTAINING A SUBSTITUTED RENTING GROUP, INHIBITORS OF MNK1 AND / OR MNK2 QUINASES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USE OF THE SAME FOR THE TREATMENT OF METABOLIC DISORDERS SUCH AS DIABETES AND OTHERS
EA201201191A1 (en) * 2010-02-26 2013-04-30 Бёрингер Ингельхайм Интернациональ Гмбх 4- [CYCLOALKYLOXY (HETERO) ARYLAMINO] THIENO [2,3-D] PYRIMIDINES THAT HAVE INHIBITING ACTIVITY WITH RESPECT TO MNKL / MNK2 INTENDED FOR PHARMACEUTICAL COMPOSITIONS
EP2539344B1 (en) * 2010-02-26 2014-10-15 Boehringer Ingelheim International GmbH Halogen or cyano substituted thieno[2,3-d]pyrimidines having mnk1/ mnk2 inhibiting activity for pharmaceutical compositions
UY33241A (en) * 2010-02-26 2011-09-30 Boehringer Ingelheim Int ? Tienopyrimidines containing heterocycloalkyl for pharmaceutical compositions ?.
CA2793170C (en) * 2010-03-15 2018-04-17 Virginia Commonwealth University Aerosolized dapsone as a therapy for inflammation of the airway and abnormal mucociliary transport
JP6235001B2 (en) 2012-05-21 2017-11-22 バイエル・ファルマ・アクティエンゲゼルシャフト Substituted benzothienopyrimidine
EP2852596B1 (en) 2012-05-21 2016-06-22 Bayer Pharma Aktiengesellschaft Thienopyrimidines
TW201412740A (en) 2012-09-20 2014-04-01 Bayer Pharma AG Substituted pyrrolopyrimidinylamino-benzothiazolones
US20160159816A1 (en) 2013-02-01 2016-06-09 Bayer Pharma Aktiengesellschaft Substituted thienopyrimidines and pharmaceutical use thereof
EP2951175B1 (en) 2013-02-01 2017-10-04 Bayer Pharma Aktiengesellschaft Substituted pyrazolopyrimidinylamino-indazoles
CA2903925A1 (en) 2013-03-06 2014-09-12 Bayer Pharma Aktiengesellschaft Substituted thiazolopyrimidines
WO2014145022A1 (en) 2013-03-15 2014-09-18 President And Fellows Of Harvard College Hybrid necroptosis inhibitors
TW201605867A (en) * 2013-11-20 2016-02-16 拜耳製藥公司 Thienopyrimidines
WO2015162518A1 (en) 2014-04-25 2015-10-29 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
CN107982282B (en) * 2017-12-14 2020-02-18 吉林大学 A gargle for the relief and treatment of pharyngitis
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections
CN114796264A (en) * 2021-01-27 2022-07-29 北京北工大科技园有限公司 Application of gold complex in preparation of medicine for treating novel coronavirus pneumonia
WO2022236182A1 (en) * 2021-05-07 2022-11-10 Fimbrion Therapeutics, Inc. Compounds and methods of treating tuberculosis
CN114957280B (en) * 2021-12-31 2024-09-17 成都赜灵生物医药科技有限公司 Thiophene [2,3-d ] pyrimidine derivative and application thereof
CN114736128A (en) * 2022-03-10 2022-07-12 青岛科技大学 A kind of method for preparing o-aminophenyl ether
CN118416038B (en) * 2024-04-28 2024-11-12 中国海洋大学 Application of 2-(2-methylpropoxy)aniline in preparing medicine for treating inflammatory diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000056738A1 (en) * 1999-03-23 2000-09-28 Astrazeneca Ab Pyridine and pyrimidine derivatives and their use as inhibitors of cytokine mediated disease
WO2005042537A1 (en) * 2003-10-22 2005-05-12 Bristol-Myers Squibb Company Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
WO2006136402A1 (en) * 2005-06-22 2006-12-28 Develogen Aktiengesellschaft Thienopyrimidines for pharmaceutical compositions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000056738A1 (en) * 1999-03-23 2000-09-28 Astrazeneca Ab Pyridine and pyrimidine derivatives and their use as inhibitors of cytokine mediated disease
WO2005042537A1 (en) * 2003-10-22 2005-05-12 Bristol-Myers Squibb Company Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
WO2006136402A1 (en) * 2005-06-22 2006-12-28 Develogen Aktiengesellschaft Thienopyrimidines for pharmaceutical compositions

Also Published As

Publication number Publication date
WO2007059905A9 (en) 2007-11-01
WO2007059905A2 (en) 2007-05-31

Similar Documents

Publication Publication Date Title
WO2007059905A3 (en) Thienopyrimidines treating inflammatory diseases
WO2008079291A3 (en) Substituted heterocycles and methods of use
WO2005066163A3 (en) Thiophene derivatives as chk 1 inihibitors
WO2005070891A3 (en) Compounds and methods of use
WO2009091374A3 (en) Fused heterocyclic derivatives and methods of use as c-met inhibitors
WO2008086014A3 (en) Bis-aryl amide derivatives useful for the treatment of cancer
WO2008006547A3 (en) Pyrrolopyrimidines for pharmaceutical compositions
PH12012501691A1 (en) Heterocycloalkyl-containing thienopyrimidines for pharmaceutical compositions
MY167135A (en) Fused heterocyclic derivatives and methods of use
MY177111A (en) Substituted amide derivatives and methods of use
WO2008076046A8 (en) Novel 2-amino-5, 5-diaryl-imidazol-4-ones
ZA200707591B (en) Dihyrothienopyrimidines for the treatment of inflammatory diseases
WO2009011850A3 (en) Novel therapeutic compounds
WO2008064018A8 (en) Thienopyrimidinones for treatment of inflammatory disorders and cancers
WO2010108074A3 (en) Inhibitors of pi3 kinase
ZA201001304B (en) Compositions for the treatment of neoplastic diseases
CR9347A (en) PIRIMIDINE DERIVATIVES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS
WO2008005565A3 (en) Antiviral phosphinate compounds
WO2007048070A3 (en) Pyrrolo-pyridine derivatives for the treatment of cancer diseases
WO2007005668A3 (en) Bis-aryl kinase inhibitors and their use in the treatment of inflammation, angiogenesis and cancer
WO2010014253A3 (en) Ant4 inhibitor compounds and methods of use thereof
WO2007109279A3 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
WO2007011760A3 (en) Inhibitors of mitotic kinesin
IL183591A0 (en) Novel process for the manufacture of 3-pyrrolidin-2-yl-propionic acid derivatives
PL2099769T3 (en) 6-oxo.-1, 6-dihydropyrimidin-2-yls in the treatment of proliferative diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06818649

Country of ref document: EP

Kind code of ref document: A2